The histograms of distributions of preoperative serum albumin levels (preAlb) and postoperative decrease in serum albumin (ΔAlb). by Fumihiko Kinoshita (6655172)

Image_5_Where Are We on the Animal Welfare Map? Using GIS to Assess Stakeholder Diversity and Inclusion.TIFF by Kevin C. Roberts (11828714)

Data Sheet 2_Reducing ocular Demodex using petroleum jelly may alleviate dry eye syndrome, blepharitis, facial dermatoses, ocular and respiratory allergies, and decrease associated... by Diana E. Senior-Fletcher (22090340)

“…Mean yearly issues of anti-allergy and antimicrobial medicines reduced from 15.6 (range 8–25) to 1.8 (range 0–4), representing an 88.5% decrease for Volunteer 1 and from 5.8 (range 3–9) and 14.2 issues (range 9–24) to zero for both Volunteer 2 and Volunteer 13 respectively, representing 100% reductions in prescribing. …”

Data Sheet 1_Reducing ocular Demodex using petroleum jelly may alleviate dry eye syndrome, blepharitis, facial dermatoses, ocular and respiratory allergies, and decrease associated... by Diana E. Senior-Fletcher (22090340)

“…Mean yearly issues of anti-allergy and antimicrobial medicines reduced from 15.6 (range 8–25) to 1.8 (range 0–4), representing an 88.5% decrease for Volunteer 1 and from 5.8 (range 3–9) and 14.2 issues (range 9–24) to zero for both Volunteer 2 and Volunteer 13 respectively, representing 100% reductions in prescribing. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. by Joanna Gutral (12101779)

Distribution of mean seasonal rainfall in the study area. by Menbere Sahilu (18195856)

Subjects: